Logo

Henlius' HLX04-O (biosimilar- bevacizumab) Receives the US FDA's IND Approval for wAMD

Share this

Henlius' HLX04-O (biosimilar- bevacizumab) Receives the US FDA's IND Approval for wAMD

Shots:

  • The US FDA has approved the IND application of HLX04-O for the treatment of wAMD
  • The P-III clinical study of HLX04-O will be conducted to further evaluate the efficacy and safety of HLX04-O in patients with wAMD in the near future. The study will enroll 388 patients from Chinese mainand- Australia- Russian Federation- Singapore- Spain and Poland
  • Henlius and Essex will speed up the global clinical trials of HLX04-O and apply approval in different countries and regions across the globe based on the research results

  Ref: Henlius | Image: Henlius

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions